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Abstracts / Osteoarthritis and Cartilage 22 (2014) S57–S489S296role of T cells, primarily Th17 cells, are nowwell recognised. On the other
hand data about immunological proﬁle in OA are limited, because OA has
long been regarded in the past as a no inﬂammatory disease. Our study
aim tomeasure thedistribution and the activationdegreeofCD4þ Th17 in
peripheral blood of OA, RA and age-matched healthy controls.
Methods: Patients with established diagnosis of RA according to ACR/
EULAR 2010 criteria, knee or hip OA according to ACR criteria and vol-
unteers healthy blood donors were eligible. Other inclusion criteria were
a DAS28 between 3.2 and 5.1 or a WOMAC Likert score more than 50,
respectively. Exclusion criteria were the presence of other autoimmune
diseases, tumours or secondary osteoarthritis. Finally no changes in
rheumatologic drugs were allowed from 3 months before enrolment.
Multichannel ﬂow cytometry was used for T cells subpopulation dis-
tinguishing and quantiﬁcation using monoclonal antibodies against CD3,
CD4, CD8, CCR6, CD38, CXCR3 and HLA DR. Participants were informed
about the aim of the project and gave their written consent. The project
was accepted by the Local Ethic Committee.
Results: We analysed blood samples of 91 subjects (75 females, 16
males). 15 Patients with well-deﬁned RA, 56 with hip or knee OA and 20
healthy controls. Mean age was 45  2.7 years old (p > 0.05 between
groups). Blood samples from the RA patients had signiﬁcantly higher
count of CD4þCD38þDRþ (activated CD4 T cells) and Th17
(CCR6þCXCR3-) cells as compared to OA patients and control group
(Figure) (P < 0.01). Furthermore the samples from the OA patients had
an higher percentage of activated CD4 T cells and Th17 cells as com-
pared to control group (P < 0.05)
Conclusion: According to the latest view of OA disease pathogenesis,
our preliminary results give support to the hypothesis that OA may also
(like RA) be a disease with an immunological/inﬂammatory involve-
ment. In fact it seems that there is a quantitative but non qualitative
difference in Th17 cells proﬁle, including the expression of activation
markers, between RA and OA.
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PERIODONTITIS DISEASE AS A MODEL OF INFLAMMATION AND
BONE REMODELLING TO STUDY OSTEOARTHRITIS DRUG EFFECTS.
RESULTS FROM A PILOT STUDY IN OA PATIENTS TREATED WITH
CHONDROITIN SULFATE
A. Gurt y, C. Lopez y, M.J. Sales y, L. Tio z, P. Benito x, J. Monfort x. yCentro
de Atencion Primaria Vila Olímpica. PAMEM., Barcelona, Spain;
zGRICIC.FIMIM, Barcelona, Spain; xHosp. del Mar of Barcelona,
Barcelona, Spain
Purpose: Periodontitis is an inﬂammatory disease that affects 70% of the
adult population. Its most important consequence is the loss of bone
supporting the teeth. Its medical treatment so far has not shown to be
effective so only different surgical techniques are useful in advanced
stages. Osteoarthritis (OA) and periodontitis share physiopathological
characteristics. OA patients also suffer from an important inﬂammatory
component in the soft tissue and bone structural modiﬁcations. Because
of the evolution of the disease, development of new treatments is dif-
ﬁcult. Periodontitis could be a model for the study of OA, where thechanges of tissues could be observed in amore directlyway. Chondroitin
sulfate (CS) has shownapositive effect in different chronic inﬂammatory
diseases such as psoriasis, inﬂammatory bowel disease and OA. Perio-
dontitis is the most prevalent inﬂammatory disease, but currently
without speciﬁc treatment. New approaches for a safety and effective
pharmacological treatments are required. The purpose of this study was
to demonstrate that an effective drug inOApathologymay improve both
the inﬂammatory symptoms and the bone resorption occurred in
periodontal disease. This improvement would be reﬂected in changes in
biochemical markers of inﬂammation and bone metabolism.
Methods: Observational, prospective, pilot study in 26 patients diag-
nosed with knee OA and periodontitis. Patients were treated with CS
800 mg/day(Condrosan, Bioiberica SA) for 12 months. The L€oe and
Silness gingival index (used to assess soft tissue damage) and CPITN
(Community Periodontal Index of Treatment Needs) index were eval-
uated at 0, 3, 6, 9 and 12 months with saliva collection. Orthopanto-
mographys were performed at 0, 6 and 12 months to evaluate bone
damage. Vertical lesions were measured using a periodontal probe at 0,
6 and 12 months. Different concentration of inﬂammatory markers
(TNF -a, IL -1b, IL-18 and PGE2) and bonemetabolism (OPG, OPN, RANKL
and MMP-8) were quantiﬁed in the saliva by ELISA or protein array.
During the study, patients were asked to continue their usual oral
hygiene without additional treatments. Statistical analysis was per-
formed using Wilcoxon test for paired samples.
Results: L€oe and Silness index decreased signiﬁcantly after 6, 9 and 12
monthsof treatment (p¼0.004,0.007and0.002 respectively). In contrast,
no signiﬁcant changeswere observed in CPTIN values, probably due to the
fact that only the most affected tooth is studied and it can differ between
visits. Both orthopantomography as well as the vertical lesions evolution,
showed signiﬁcant improvement at 12 months (p ¼ 0.009) and 6 and 12
months respectively (p ¼ 0.002 and p ¼ 0.016). For biochemical analysis
results, patients with no gingival improvement were used as control
group.The results showabetterperformance in thegroupof responders to
treatment for inﬂammatory markers PGE-2, TNF-a and IL-1b , as well as
bone metabolismmarkers, OPN, MMP -8, and the ratio OPG/RANKL. Res-
ponders groups PGE2 levels showed a signiﬁcant decreased after 12
months of treatment (p¼ 0.033), whereas IL-1b levels in non responding
patients suffered a signiﬁcant increased after 3 and 6months of treatment
(p¼ 0.017)
Conclusions: CS improves soft tissue inﬂammation after 6 months of
treatment and bone support at 12 months in periodontal disease,
similar to the already known effect of the drug in OA disease. This
improvement is reﬂected in markers of inﬂammation and bone
metabolism in saliva. Due to its efﬁcacy and safety proﬁle, CS is
postulated as a good candidate for the treatment of this disease.Intervertebral disc
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ADIPOKINES AND THE INTERVERTEBRAL DISC: DOES A
BIOCHEMICAL LINK EXIST BETWEEN OBESITY AND BACK PAIN?
A. Segar y,z, K. Edwards x, J. Fairbank y, J. Urban x. yNufﬁeld Dept. of
Orthopaedics, Rheumatology and Musculoskeletal Sci., Univ. of Oxford,
OXFORD, United Kingdom; zDept. of Physiology, Anatomy and Genetics,
Univ. of Oxford, Oxford, United Kingdom; xDept. of Physiology, Anatomy
and Genetics, Univ. of Oxford, Oxford, United Kingdom
Purpose: Obesity is a signiﬁcant risk factor for development of low back
pain and intervertebral disc (IVD) degeneration. The mechanism
underlying this link is unclear but is commonly thought to arise from
altered loading. However, adipokines such as leptin and adiponectin,
produced by adipose tissue, are now known to be involved in degra-
dative processes particularly in articular joints. We propose a similar
link exists between these adipokines and intervertebral disc degener-
ation. Obese individuals are known to have higher concentrations of
serum adipokines, there is increased local fat in chronic spinal con-
ditions potentiating an increase in local adipokine levels and disc cells
are reported to have leptin receptors and can synthesise leptin.
The aim of the study was to identify responses of nucleus pulposus (NP)
and outer annulus ﬁbrosus (OA) cells to leptin and adiponectin. Once
identiﬁed, we proceeded to determine if synergistic effects exist in the
presence of other pro-inﬂammatory cytokines.
Methods: Bovine intervertebral discs were used as a model system.
Freshly isolated NP and OA cells embedded in 3D alginate beads, were
Abstracts / Osteoarthritis and Cartilage 22 (2014) S57–S489 S297cultured under varying concentrations of leptin alone, adiponectin
alone or together with the pro-inﬂammatory cytokines TNF-a and IL-1b.
Lactate was used to assess energy metabolism. Active and proMMP-2
and -9 in the culture medium were measured using gelatin zymog-
raphy. Western blotting was used to assess levels of MMP-1, -3 and -13
and quantitative real-time PCR was used to assess expression levels of
anabolic and catabolic genes.
Results: Leptin inﬂuencedcellularmetabolismofboth theNPandOAcells.
Furthermore leptin led to decreased glycosaminoglycan production and
signiﬁcantly increased production of MMP-2, -3 and -9, by both cell types
at the protein level. Similar results were seen with adiponectin. Gene
expressionof thematrixgenes aggrecan, collagen I and collagen II fellwith
increasing concentrations of leptin. Most importantly, in the presence of
leptin, the expression of both TNF-a and IL-1b were signiﬁcantly upre-
gulated. Addition of leptin to medium containing the pro-inﬂammatory
cytokines, demonstrated a marked synergistic effect on energy metabo-
lism and the production of certain proteases, especially MMP-2.
Conclusions: Our results show that leptin can upregulate proteases
involved in degenerative processes in the IVD, and that this effect is
potentiated in the presence of pro-inﬂammatory cytokines such as TNF-a
and IL-1b. Leptin levels are increasedmarkedly inobesepatientsandhence
a biochemical mechanism may be involved in the association between
obesity, disc degeneration and back pain particularly in an inﬂammatory
environment
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OSTEOGENIC DIFFERENTIATION OF IVD CELLS: INDUCTION OF
BIOLOGICAL FUSION.
S.A. Turner y,z, B. Balain y, S.M. Eisenstein y, S. Roberts y,z. yRobert Jones
& Agnes Hunt Orthopaedic Hosp., Oswestry, United Kingdom; z ISTM, Keele
Univ., Keele, United Kingdom
Purpose: Much focus has been placed on the development of methods
for biological repair or regeneration of the degenerate intervertebral
disc (IVD), with varying success in humans and animal models. The
current ‘gold standard’ treatment for IVD degeneration is fusion of the
vertebral space, requiring invasive and painful surgery with extensive
metalwork. Unlike IVD regeneration, little emphasis has been placed on
the development of biological fusion. We have investigated the ability
for IVD cells to differentiate osteogenically and aim to determine the
‘best’ method for bone formation. Ideally, this will result in the devel-
opment of a method to induce the degenerate (and painful) IVD to turn
itself to bone and fuse the vertebral space and thus remove the need for
major surgery for the patient.
Methods: Monolayer cultures of IVD cells and mesenchymal stromal
cells (MSCs) isolated from samples obtained from patients undergoing
routine surgery for IVD disorders were treated with standard culture
media, osteogenic media (including 100 nM dexamethasone, 10 nM b-
glycerophosphate and 50 mM L-ascorbic acid-2-phosphate) or 1,25Cartilage damage index stratiﬁed by baseline medial JSN grade
Cartilage Measure JSN ¼ 0(n ¼ 43) mean (SD) JSN ¼ 1(n ¼ 25) mean (SD
Femur CDI (Baseline) 747.95 (143.69) 664.55 (98.89)
Femur CDI (Baseline) 389.56 (78.60) 368.12 (59.16)
Tibiofemoral CDI (Baseline) 1137.50 (203.22) 1032.70 (149.94)
Femur CDI (Change) 2.95 (48.95) 19.33 (57.29)
Tibia CDI (Change) 9.31 (26.30) 26.25 (26.41)
Tibiofemoral CDI (Change) 12.26 (63.30) 45.58 (71.29)
Cartilage damage index stratiﬁed by baseline KL grade
Cartilage Measure KL ¼ 0 (n ¼ 4)
mean (SD)




Femur CDI (Baseline) 676.99 (90.01) 657.45 (151.46) 712.8
Tibia CDI (Baseline) 416.01 (97.53) 350.20 (58.16) 378.3
Tibiofemoral CDI
(Baseline)
1093.0 (179.14) 1007.7 (192.65) 1091.
Femur CDI (Change) 38.28 (57.02) 15.08 (52.16) 4.95
Tibia CDI (Change) 43.46 (50.24) 18.96 (27.01) 14.3
Tibiofemoral
CDI (Change)
81.74 (106.83) 34.04 (58.88) 19.2dihydroxyvitamin D3 (VitD3) at 0.1, 1 or 10 nM for 21 days. Treated cells
were histochemically stained for alkaline phosphatase activity, a
marker of osteogenic differentiation.
Results: VitD3 produced a dose-related increased production of alka-
line phosphatase by both MSCs and IVD cells, compared to standard
culture media. However, the response to osteogenic media was greater.
Generally, the response of IVD cells under all culture conditions was less
than seen with MSCs, although the trends were always the same.
Conclusions: These preliminary results show that VitD3 can induce
osteogenic differentiation of IVD cells, but often to a lesser extent than
media containing dexamethasone, b-glycerophosphate and L-ascorbic
acid-2-phosphate or that seen from MSCs. This is encouraging in the
search for a method to induce biological fusion of the vertebral space,
but further work using other osteogenic factors is required.Joint Morphology and/or Morphometry
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STUDY OF CARTILAGE DAMAGE INDEX WITH JOINT SPACE
NARROWING AND KELLGREN-LAWRENCE GRADE
M. Zhang y, J.B. Driban y, L. Price y, D. Harper y, G.H. Lo z, E. Miller x,
R.J. Ward y, T.E. McAlindon y. y Tufts Med. Ctr., Boston, MA; zMichael E.
DeBakey VA Med. Ctr./Baylor Coll. of Med., Huston, TX, USA; x Tufts Univ.,
Medford, MA, USA
Purpose: While cartilage morphometry on magnetic resonance (MR)
imaging is increasingly accepted as an outcome measure for clinical
trials among individuals with osteoarthritis (OA), it remains bur-
densome, which limits its utility in large studies. We recently
developed a rapid knee cartilage quantiﬁcation method that has
been validated with joint space width, joint space narrowing, static
alignment. As another step in our validation process we wanted to
conﬁrm the cartilage damage index (CDI) can also detect a pre-
viously described association between cartilage damage and Kellg-
ren-Lawrence (KL) grade with the exception of KL ¼ 2, which has
cartilage thickening.
Methods: We selected 102 participants from the Osteoarthritis
Initiative (OAI) who had a diverse range of JSN (0 to 3) and KL
grades (0 to 4) and for whom 3D double-echo steady-state sagittal
images were available. MRIs were obtained on four 3-Tesla systems
(0.37 mm  0.37 mm, 0.7 mm slice thickness). One reader used
customized software to measure the CDI in the medial femur and
tibia from the baseline and 24-month visit (ICCs3,1 ¼ 0.95 to 0.99).
Central readers determined semi-quantitative assessments of
radiographic knee OA severity (KL grade and modiﬁed OARSI-atlas
based medial JSN scores) using the weight-bearing posterior-ante-
rior ﬁxed-ﬂexion knee radiographs from the baseline OAI visit
(radiographic readings are publicly available at http://oai.epi-ucsf.
org/; kxr_sq_bu_00 [version 0.5]). To account for different skeletal) JSN ¼ 2(n ¼ 26) mean (SD) JSN ¼ 3(n ¼ 3) mean (SD) p-value for Trend
521.57 (108.73) 308.95 (171.85) <0.01
292.77 (71.57) 149.53 (113.88) <0.01
814.34 (152.48) 458.48 (278.78) <0.01
47.15 (60.92) 99.30 (90.47) <0.01
45.00 (41.63) 43.86 (44.65) <0.01
92.15 (82.51) 143.2 (134.52) <0.01
2 (n ¼ 40)
(SD)
KL ¼ 3 (n ¼ 34)
mean (SD)




4 (117.43) 599.35 (169.07) 527.67 (332.25) 0.02
3 (67.55) 330.49 (94.90) 248.59 (169.46) <0.01
2 (170.23) 929.83 (248.63) 776.26 (497.49) 0.01
(52.98) 40.33 (58.57) 38.70 (107.60) 0.15
3 (27.37) 36.19 (38.95) 36.19 (38.95) 0.23
9 (70.13) 76.52 (79.70) 65.35 (143.93) 0.12
